
PT J
AU Joyner, RL
   Hollenbaugh, JA
   D'Aquila, D
   Fishman, M
   Cohen, SM
   Holdai, V
   Benner, JD
AF Joyner, Robert L.
   Hollenbaugh, Joseph A.
   D'Aquila, Donald
   Fishman, Marc
   Cohen, Steven M.
   Holdai, Veera
   Benner, Jeffrey D.
TI Bioabsorbable, subcutaneous naltrexone implants mitigate
   fentanyl-induced respiratory depression at 3 months-A pilot study in
   male canines
SO PHYSIOLOGICAL REPORTS
LA English
DT Article
DE bioabsorbable; canines; fentanyl; implants; naltrexone; respiratory
   depression
AB The aim of this study is to determine if extended-release, bioabsorbable, subcutaneous naltrexone (NTX) implants can mitigate respiratory depression after an intravenous injection (IV) of fentanyl. Six different BIOabsorbable Polymeric Implant Naltrexone (BIOPIN) formulations, comprising combinations of Poly-d,l-Lactic Acid (PDLLA) and/or Polycaprolactone (PCL-1 or PCL-2), were used to create subcutaneous implants. Both placebo and naltrexone implants were implanted subcutaneously in male dogs. The active naltrexone implants consisted of two doses, 644 mg and 1288 mg. A challenge with IV fentanyl was performed in 33 male dogs at 97-100 days after implantation. Following the administration of a 30 mu g/kg intravenous fentanyl dose, the placebo cohort manifested a swift and profound respiratory depression with a similar to 50% reduction in their pre-dose respiratory rate (RR). The BIOPIN NTX-implanted dogs were exposed to escalating doses of intravenous fentanyl (30 mu g/kg, 60 mu g/kg, 90 mu g/kg, and 120 mu g/kg). In contrast, the dogs implanted with the BIOPIN naltrexone implants tolerated doses up to 60 mu g/kg without significant respiratory depression (<50%) but had severe respiratory depression with fentanyl doses of 90 mu g/kg and especially at 120 mu g/kg. Bioabsorbable, extended-release BIOPIN naltrexone implants are effective in mitigating fentanyl-induced respiratory depression in male canines at about 3 months after implantation. This technology may also have potential for mitigating fentanyl-induced respiratory depression in humans.
C1 [Joyner, Robert L.; D'Aquila, Donald; Benner, Jeffrey D.] TidalHealth Peninsula Reg Salisbury, Richard A Henson Res Inst, 26627 Pemberton Dr, Salisbury, MD 21801 USA.
   [Hollenbaugh, Joseph A.] Labcorp, Greenfield, IN USA.
   [Fishman, Marc] Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD USA.
   [Fishman, Marc] Maryland Treatment Ctr, Baltimore, MD USA.
   [Cohen, Steven M.; Benner, Jeffrey D.] LLC Dba Akyso, Drug Delivery Co, Salisbury, MD USA.
   [Holdai, Veera] Salisbury Univ, Dept Math Sci, Salisbury, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University System of
   Maryland; Salisbury University
RP Benner, JD (corresponding author), TidalHealth Peninsula Reg Salisbury, Richard A Henson Res Inst, 26627 Pemberton Dr, Salisbury, MD 21801 USA.
EM jffbenner@gmail.com
RI Joyner, Robert/A-3136-2009
OI Joyner, Robert/0000-0002-7228-2671; Benner, Jeffrey/0000-0002-0350-2204;
   Cohen, Steven/0000-0002-6633-8173
FU HHS | NIH | National Institute on Drug Abuse (NIDA) [UG3 DA048338]
FX HHS | NIH | National Institute on Drug Abuse (NIDA), Grant/Award Number:
   UG3 DA048338
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2051-817X
J9 PHYSIOL REP
JI PHYSIOL. REP.
PD AUG
PY 2024
VL 12
IS 15
AR e16176
DI 10.14814/phy2.16176
PG 13
WC Physiology
WE Emerging Sources Citation Index (ESCI)
SC Physiology
GA C1W4U
UT WOS:001287331500001
PM 39118319
OA gold, Green Published
DA 2024-02-08
ER